Therefore, more selective and personalized therapies incorporating drugs targeting mechanisms induced by recurrent AML mutations have been studied in various clinical trials and led to the approval of AML treatment regimens including hypomethylating agents (HMAs; azacitidine, decitabine), pro-apoptotic agents (venetoclax), FLT3 kinase inhibitors (gilteritinib, midostaurin, sorafenib, quizartinib, crenolanib), and IDH inhibitors (ivosidinib, enasidinib). This evidence concerns the gene IDH1 and acute myeloid leukemia.